sotagliflozin (Pending FDA Approval)

Brand and Other Names:Zynquista
  • Print

Dosing & Uses

AdultPediatric

Diabetes Mellitus Type I

Pending FDA approval for adults with type I diabetes mellitus in combination with insulin therapy

Safety and efficacy not established

Next:

Pharmacology

Mechanism of Action

Dual inhibitor of selective sodium-glucose transporters 1 and 2 (SGLT-1, SGLT-2)

SGLT1 inhibition improves glucose homeostasis by reducing dietary glucose absorption in the intestine and by increasing the release of gastrointestinal incretins (eg, glucagon-like peptide-1 [GLP-1] agonists)

SGLT2 is expressed in the proximal renal tubules and is responsible for the majority of the reabsorption of filtered glucose from the tubular lumen; SGLT2 inhibitors reduce glucose reabsorption and lower the renal threshold for glucose, thereby increasing urinary glucose excretion

Previous
Next:

Images

Previous
Next:
Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.